⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11669741 | 0.88 | OR51E2 (0.38) | — | |
| SCHEMBL257071 | 0.83 | THRB (0.45) | — | |
| SCHEMBL14107874 | 0.81 | CRBN (0.40) | — | |
| SCHEMBL9029619 | 0.80 | THRB (0.49) | — | |
| Hydrochloric Acid SCHEMBL9029064 | 0.79 | THRB (0.48) | — | |
| SCHEMBL974631 | 0.79 | THRB (0.51) | — | |
| SCHEMBL211676 | 0.78 | — | — | |
| SCHEMBL8163695 | 0.78 | — | — | |
| SCHEMBL14431370 | 0.78 | — | — | |
| SCHEMBL25959798 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116867788-B | 4-Aminoquinazoline compounds | ASTELLAS PHARMA INC. (JP) | 2026-05-26 | — | — | CN | claimed |
| WO-2022173033-A1 | 4-AMINOQUINAZOLINE COMPOUNDS | アステラス製薬株式会社 | 2022-08-18 | — | — | WO | claimed |
| US-5124379-A | SELF-EXTINGUISHING POLYMERIC COMPOSITIONS | PRESIDENZA DEL CONSIGLIO DEI MINISTRI UFFICIO DEL MINISTRO PER IL COORDINAMENTO DELLE INIZIATIVE PER LA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1992-06-23 | — | — | US | claimed |
| CN-116867788-B | 4-Aminoquinazoline compounds | ASTELLAS PHARMA INC. (JP) | 2026-05-26 | — | — | CN | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024057277-A1 | DIAGNOSTIC PET IMAGING OF CARDIAC AMYLOIDOSIS | Beijing Lado Technology Co., Ltd. (CN) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007081897-A2 | FUSED TRIAZOLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-4112049-A | PIPERAZINONES | THE DOW CHEMICAL COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4100256-A | TO HYDROGEN SULFIDE AND CARBON DIOXIDE | THE DOW CHEMICAL COMPANY (US) | 1978-07-11 | — | — | US | disclosed |